SD Biosensor, Inc, an in-vitro diagnostic company, provides point-of-care diagnostic solutions in South Korea and internationally. The company’s products include STANDARD Q, which provides various rapid test parameters comprising COVID-19 products and other parameters; STANDARD F, a multi-parametric and random accessible FIA system that provides diagnostic results to the laboratories; and STANDARD E, an enzyme linked immunosorbent assay for mass screening tests. Its products also include STANDARD M, a point-of-care MDx system for clinical decision making near-the-patient, which include analyzers, assay menus, qPCR reagents, and NA extraction kits; procell Dx, an in vitro diagnostic products for the diagnosis of infectious disease, such as tuberculosis and SARS-CoV-2, and for checking the immune status of individuals through the interferon gamma release assay; and blood glucose meters. The company was founded in 2010 and is headquartered in Suwon, South Korea.
Metrics to compare | 137310 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship137310PeersSector | |
---|---|---|---|---|
P/E Ratio | −11.3x | −4.7x | −0.5x | |
PEG Ratio | −0.19 | −0.15 | 0.00 | |
Price/Book | 0.4x | 1.7x | 2.6x | |
Price / LTM Sales | 1.7x | 3.3x | 3.2x | |
Upside (Analyst Target) | −10.6% | 32.3% | 43.8% | |
Fair Value Upside | Unlock | 4.5% | 8.1% | Unlock |